Trial Profile
Comparison of the Immunogenicity and Safety of Three Consistency Lots of V260 in Healthy Infants
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Rotavirus W179-9 vaccine (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme
- 31 Jul 2008 Status changed from active, no longer recruiting to completed.
- 08 Nov 2005 New trial record.